Skip to main content
SpringerLink
Log in

Stereotactic Ablative Radiotherapy (SAbR) for Primary Renal Cell Carcinoma

  • Chapter
  • First Online:
Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy

  • 1371 Accesses

Abstract

Although renal cell cancer (RCC) was shown to be radioresistant to conventionally fractionated radiation therapy (RT) both in vitro and in vivo, mounting preclinical and clinical evidence suggests that it is quite sensitive to hypofractionated RT, particularly stereotactic ablative radiotherapy (SAbR). In the setting of primary RCC, SAbR has been applied effectively in multiple retrospective and early phase prospective trials with favorable toxicity. In this chapter, we will review the current literature and cover the technical considerations for the setup, treatment planning, and delivery of SAbR for primary RCC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

4D CT:

4-dimensional computer tomography

AUA:

American Urologic Association

CBCT:

Cone-beam computed tomography

CNS:

Central nervous system

CSS:

Cancer-specific survival

CT:

Computed tomography

CTV:

Clinical target volume

eGFR:

Estimated glomerular filtration rate

GTV:

Gross target volume

IMRT:

Intensity-modulated radiation therapy

IORT:

Intraoperative radiation therapy

ITV:

Internal target volume

LC:

Local control

MRI:

Magnetic resonance imaging

NCCN:

National Comprehensive Cancer Network

OS:

Overall survival

PFS:

Progression-free survival

PTV:

Planning target volume

RCC:

Renal cell cancer

RFA:

Radiofrequency ablation

RT:

Radiation therapy

SAbR:

Stereotactic ablative radiation therapy

SBRT:

Stereotactic body radiation therapy

VMAT:

Volumetric modulated arc therapy

References

  1. American Cancer Society. Cancer facts and figures 2012. 2012.

    Google Scholar 

  2. American Cancer Society. Key Statistics About Kidney Cancer. 2018; Available from: https://www.cancer.org/cancer/kidney-cancer/about/keystatistics.html.

  3. Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology. 1998;51(2):203–5.

    Article  CAS  PubMed  Google Scholar 

  4. Smith SJ, Bosniak MA, Megibow AJ, Hulnick DH, Horii SC, Raghavendra BN. Renal cell carcinoma: earlier discovery and increased detection. Radiology. 1989;170(3. Pt 1):699–703.

    Article  CAS  PubMed  Google Scholar 

  5. Belldegrun A, Tsui KH, deKernion JB, Smith RB. Efficacy of nephron-sparing surgery for renal cell carcinoma: analysis based on the new 1997 tumor-node-metastasis staging system. J Clin Oncol. 1999;17(9):2868–75.

    Article  CAS  PubMed  Google Scholar 

  6. Fergany AF, Hafez KS, Novick AC. Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup. J Urol. 2000;163(2):442–5.

    Article  CAS  PubMed  Google Scholar 

  7. Herr HW. Partial nephrectomy for unilateral renal carcinoma and a normal contralateral kidney: 10-year followup. J Urol. 1999;161(1):33–4; discussion 34–5.

    Article  CAS  PubMed  Google Scholar 

  8. Lee CT, Katz J, Shi W, Thaler HT, Reuter VE, Russo P. Surgical management of renal tumors 4 cm. or less in a contemporary cohort. J Urol. 2000;163(3):730–6.

    Article  CAS  PubMed  Google Scholar 

  9. Lee DI, McGinnis DE, Feld R, Strup SE. Retroperitoneal laparoscopic cryoablation of small renal tumors: intermediate results. Urology. 2003;61(1):83–8.

    Article  PubMed  Google Scholar 

  10. Lerner SE, Hawkins CA, Blute ML, Grabner A, Wollan PC, Eickholt JT, et al. Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery. J Urol. 1996;155(6):1868–73.

    Article  CAS  PubMed  Google Scholar 

  11. Lerner SE, Hawkins CA, Blute ML, Grabner A, Wollan PC, Eickholt JT, et al. Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery. J Urol, 2002. 1996;167(2 Pt 2):884–9; discussion 889–90.

    Google Scholar 

  12. Morgan WR, Zincke H. Progression and survival after renal-conserving surgery for renal cell carcinoma: experience in 104 patients and extended followup. J Urol. 1990;144(4):852–7; discussion 857–8.

    Article  CAS  PubMed  Google Scholar 

  13. Gill IS, Desai MM, Kaouk JH, Meraney AM, Murphy DP, Sung GT, et al. Laparoscopic partial nephrectomy for renal tumor: duplicating open surgical techniques. J Urol. 2002;167(2 Pt 1):469–7; discussion 475–6.

    PubMed  Google Scholar 

  14. Wolf JS Jr, Seifman BD, Montie JE. Nephron sparing surgery for suspected malignancy: open surgery compared to laparoscopy with selective use of hand assistance. J Urol. 2000;163(6):1659–64.

    Article  PubMed  Google Scholar 

  15. Wu Z, Li M, Liu B, Cai C, Ye H, Lv C, et al. Robotic versus open partial nephrectomy: a systematic review and meta-analysis. PLoS One. 2014;9(4):e94878.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Pierorazio PM, Hyams ES, Mullins JK, Allaf ME. Active surveillance for small renal masses. Rev Urol. 2012;14(1–2):13–9.

    PubMed  PubMed Central  Google Scholar 

  17. Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DY, Uzzo RG. The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol. 2006;175(2):425–31.

    Article  PubMed  Google Scholar 

  18. Volpe A, Jewett MA. The natural history of small renal masses. Nat Clin Pract Urol. 2005;2(8):384–90.

    Article  PubMed  Google Scholar 

  19. Oda T, Miyao N, Takahashi A, Yanase M, Masumori N, Itoh N, et al. Growth rates of primary and metastatic lesions of renal cell carcinoma. Int J Urol. 2001;8(9):473–7.

    Article  CAS  PubMed  Google Scholar 

  20. Rendon RA, Stanietzky N, Panzarella T, Robinette M, Klotz L, Thurston W, et al. The natural history of small renal masses. J Urol. 2000;164(4):1143–7.

    Article  CAS  PubMed  Google Scholar 

  21. Wehle MJ, Thiel DD, Petrou SP, Young PR, Frank I, Karsteadt N. Conservative management of incidental contrast-enhancing renal masses as safe alternative to invasive therapy. Urology. 2004;64(1):49–52.

    Article  PubMed  Google Scholar 

  22. Jewett MA, Mattar K, Basiuk J, Morash CG, Pautler SE, Siemens DR, et al. Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol. 2011;60(1):39–44.

    Article  PubMed  Google Scholar 

  23. Gervais DA, McGovern FJ, Arellano RS, McDougal WS, Mueller PR. Renal cell carcinoma: clinical experience and technical success with radio-frequency ablation of 42 tumors. Radiology. 2003;226(2):417–24.

    Article  PubMed  Google Scholar 

  24. Gill IS, Novick AC, Meraney AM, Chen RN, Hobart MG, Sung GT, et al. Laparoscopic renal cryoablation in 32 patients. Urology. 2000;56(5):748–53.

    Article  CAS  PubMed  Google Scholar 

  25. Gill IS, Remer EM, Hasan WA, Strzempkowski B, Spaliviero M, Steinberg AP, et al. Renal cryoablation: outcome at 3 years. J Urol. 2005;173(6):1903–7.

    Article  PubMed  Google Scholar 

  26. Jacomides L, Ogan K, Watumull L, Cadeddu JA. Laparoscopic application of radio frequency energy enables in situ renal tumor ablation and partial nephrectomy. J Urol. 2003;169(1):49–53. discussion 53.

    Article  PubMed  Google Scholar 

  27. Ogan K, Jacomides L, Dolmatch BL, Rivera FJ, Dellaria MF, Josephs SC, et al. Percutaneous radiofrequency ablation of renal tumors: technique, limitations, and morbidity. Urology. 2002;60(6):954–8.

    Article  PubMed  Google Scholar 

  28. Pavlovich CP, Walther M, Choyke PL, Pautler SE, Chang R, Linehan WM, et al. Percutaneous radio frequency ablation of small renal tumors: initial results. J Urol. 2002;167(1):10–5.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Shingleton WB, Sewell PE Jr. Percutaneous renal tumor cryoablation with magnetic resonance imaging guidance. J Urol. 2001;165(3):773–6.

    Article  CAS  PubMed  Google Scholar 

  30. Kunkle DA, Uzzo RG. Cryoablation or radiofrequency ablation of the small renal mass: a meta-analysis. Cancer. 2008;113(10):2671–80.

    Article  PubMed  Google Scholar 

  31. Tracy CR, Raman JD, Donnally C, Trimmer CK, Cadeddu JA. Durable oncologic outcomes after radiofrequency ablation: experience from treating 243 small renal masses over 7.5 years. Cancer. 2010;116(13):3135–42.

    Article  PubMed  Google Scholar 

  32. Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH, et al. Guideline for management of the clinical T1 renal mass. J Urol. 2009;182(4):1271–9.

    Article  PubMed  Google Scholar 

  33. Gill IS, Aron M, Gervais DA, Jewett MA. Clinical practice. Small renal mass. N Engl J Med. 2010;362(7):624–34.

    Article  CAS  PubMed  Google Scholar 

  34. Goldberg SN, Grassi C, Cardella JF, Charboneau JW, Dodd GD 3rd, Dupuy DE, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol. 2009;20(7 Suppl):S377–90.

    Article  PubMed  Google Scholar 

  35. Blanco AI, Teh BS, Amato RJ. Role of radiation therapy in the management of renal cell cancer. Cancers (Basel). 2011;3(4):4010–23.

    Article  Google Scholar 

  36. Deschavanne PJ, Fertil B. A review of human cell radiosensitivity in vitro. Int J Radiat Oncol Biol Phys. 1996;34(1):251–66.

    Article  CAS  PubMed  Google Scholar 

  37. Ning S, Trisler K, Wessels BW, Knox SJ. Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer. 1997;80(12 Suppl):2519–28.

    Article  CAS  PubMed  Google Scholar 

  38. Walsh L, Stanfield JL, Cho LC, Chang CH, Forster K, Kabbani W, et al. Efficacy of ablative high-dose-per-fraction radiation for implanted human renal cell cancer in a nude mouse model. Eur Urol. 2006;50(4):795–800. discussion 800.

    Article  PubMed  Google Scholar 

  39. Shuto T, Matsunaga S, Suenaga J, Inomori S, Fujino H. Treatment strategy for metastatic brain tumors from renal cell carcinoma: selection of gamma knife surgery or craniotomy for control of growth and peritumoral edema. J Neuro-Oncol. 2010;98(2):169–75.

    Article  Google Scholar 

  40. Gerszten PC, Burton SA, Ozhasoglu C, Vogel WJ, Welch WC, Baar J, et al. Stereotactic radiosurgery for spinal metastases from renal cell carcinoma. J Neurosurg Spine. 2005;3(4):288–95.

    Article  PubMed  Google Scholar 

  41. Nguyen QN, Shiu AS, Rhines LD, Wang H, Allen PK, Wang XS, et al. Management of spinal metastases from renal cell carcinoma using stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2010;76(4):1185–92.

    Article  PubMed  Google Scholar 

  42. Ranck MC, Golden DW, Corbin KS, Hasselle MD, Liauw SL, Stadler WM, et al. Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. Am J Clin Oncol. 2013;36(6):589–95.

    Article  CAS  PubMed  Google Scholar 

  43. Wersall PJ, Blomgren H, Lax I, Kalkner KM, Linder C, Lundell G, et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol. 2005;77(1):88–95.

    Article  PubMed  Google Scholar 

  44. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11):1070–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Wang CJ, Christie A, Lin MH, Jung M, Weix D, Huelsmann L, et al. Safety and efficacy of stereotactic ablative radiation therapy for renal cell carcinoma extracranial metastases. Int J Radiat Oncol Biol Phys. 2017;98(1):91–100.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Siva S, Kothari G, Muacevic A, Louie AV, Slotman BJ, Teh BS, et al. Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach. Nat Rev Urol. 2017;14(9):549–63.

    Article  PubMed  Google Scholar 

  47. Juusela H, Malmio K, Alfthan O, Oravisto KJ. Preoperative irradiation in the treatment of renal adenocarcinoma. Scand J Urol Nephrol. 1977;11(3):277–81.

    Article  CAS  PubMed  Google Scholar 

  48. van der Werf-Messing B. Proceedings: carcinoma of the kidney. Cancer. 1973;32(5):1056–61.

    Article  PubMed  Google Scholar 

  49. Finney R. The value of radiotherapy in the treatment of hypernephroma – a clinical trial. Br J Urol. 1973;45(3):258–69.

    Article  CAS  PubMed  Google Scholar 

  50. Kjaer M, Iversen P, Hvidt V, Bruun E, Skaarup P, Bech J, et al. A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. A study by the Copenhagen Renal Cancer Study Group. Scand J Urol Nephrol. 1987;21(4):285–9.

    Article  CAS  PubMed  Google Scholar 

  51. Tunio MA, Hashmi A, Rafi M. Need for a new trial to evaluate postoperative radiotherapy in renal cell carcinoma: a meta-analysis of randomized controlled trials. Ann Oncol. 2010;21(9):1839–45.

    Article  CAS  PubMed  Google Scholar 

  52. Paly JJ, Hallemeier CL, Biggs PJ, Niemierko A, Roeder F, Martinez-Monge R, et al. Outcomes in a multi-institutional cohort of patients treated with intraoperative radiation therapy for advanced or recurrent renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2014;88(3):618–23.

    Article  PubMed  Google Scholar 

  53. Beitler JJ, Makara D, Silverman P, Lederman G. Definitive, high-dose-per-fraction, conformal, stereotactic external radiation for renal cell carcinoma. Am J Clin Oncol. 2004;27(6):646–8.

    Article  PubMed  Google Scholar 

  54. Gilson B, Lederman G, Qian G, Fastaia M, Cangiane L. Hypo-fractionated stereotactic extra-cranial radiosurgery (HFSR) for primary and metastatic renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2006;66:S349.

    Article  Google Scholar 

  55. Svedman C, Karlsson K, Rutkowska E, Sandstrom P, Blomgren H, Lax I, et al. Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney. Acta Oncol. 2008;47(8):1578–83.

    Article  CAS  PubMed  Google Scholar 

  56. Siva S, Muacevic A, Staehler M, Warner A, Gandhidasan A, Ponsky L, et al. Individual patient data meta-analysis of SBRT kidney: a report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). Int J Radiat Oncol Biol Phys. 2017;99(Supplement (2S)):S153.

    Article  Google Scholar 

  57. Siva S, Louie AV, Warner A, Muacevic A, Gandhidasan A, Ponsky L, et al. Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: a report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). Cancer. 2018;124(5):934–42.

    Article  PubMed  Google Scholar 

  58. Ponsky L, Lo SS, Zhang Y, Schluchter M, Liu Y, Patel R, et al. Phase I dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma. Radiother Oncol. 2015;117(1):183–7.

    Article  PubMed  Google Scholar 

  59. McBride SM, Wagner AA, Kaplan ID. A phase 1 dose-escalation study of robotic radiosurgery in inoperable primary renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2013;87:S84.

    Article  Google Scholar 

  60. Sun MR, Brook A, Powell MF, Kaliannan K, Wagner AA, Kaplan ID, et al. Effect of stereotactic body radiotherapy on the growth kinetics and enhancement pattern of primary renal tumors. AJR Am J Roentgenol. 2016;206(3):544–53.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Pham D, Thompson A, Kron T, Foroudi F, Kolsky MS, Devereux T, et al. Stereotactic ablative body radiation therapy for primary kidney cancer: a 3-dimensional conformal technique associated with low rates of early toxicity. Int J Radiat Oncol Biol Phys. 2014;90(5):1061–8.

    Article  PubMed  Google Scholar 

  62. Siva S, Pham DJ, Tan TH, Lam J, Bressel M, Price J, et al. Principal analysis of a phase Ib trial of stereotactic body radiation therapy (SBRT) for primary kidney cancer. Int J Radiat Oncol Biol Phys. 2016;96(2):S96.

    Article  Google Scholar 

  63. Siva S, Pham D, Kron T, Bressel M, Lam J, Tan TH, et al. Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial. BJU Int. 2017;120(5):623–30.

    Article  PubMed  Google Scholar 

  64. Staehler M, Bader M, Schlenker B, Casuscelli J, Karl A, Roosen A, et al. Single fraction radiosurgery for the treatment of renal tumors. J Urol. 2015;193(3):771–5.

    Article  PubMed  Google Scholar 

  65. Staehler MD, Schlenker B, Karl A, Spek A, Muacevic A. Single-fraction radiosurgery for the treatment of renal cell carcinoma. J Clin Oncol. 2016;34(2 Suppl):590.

    Article  Google Scholar 

  66. Svedman C, Sandstrom P, Pisa P, Blomgren J, Lax I, Kalkner KM, et al. A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol. 2006;45(7):870–5.

    Article  PubMed  Google Scholar 

  67. Siva S, Pham D, Gill S, Corcoran NM, Foroudi F. A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma. BJU Int. 2012;110(11 Pt B):E737–43.

    Article  PubMed  Google Scholar 

  68. Chang JH, Cheung P, Erler D, Sonier M, Korol R, Chu W. Stereotactic ablative body radiotherapy for primary renal cell carcinoma in non-surgical candidates: initial clinical experience. Clin Oncol (R Coll Radiol). 2016;28(9):e109–14.

    Article  CAS  Google Scholar 

  69. Siva S, Jackson P, Kron T, Bressel M, Lau E, Hofman M, et al. Impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma: establishing a dose-response relationship. Radiother Oncol. 2016;118(3):540–6.

    Article  PubMed  Google Scholar 

  70. George R, Keall PJ, Kini VR, Vedam SS, Siebers JV, Wu Q, et al. Quantifying the effect of intrafraction motion during breast IMRT planning and dose delivery. Med Phys. 2003;30(4):552–62.

    Article  CAS  PubMed  Google Scholar 

  71. Hugo G, Tenn S, Agazaryan N. An evaluation of intrafraction motion-induced error for fractionated IMRT delivery. Med Phys. 2003;30(6):1470–0.

    Google Scholar 

  72. Siva S, Pham D, Gill S, Bressel M, Dang K, Devereux T, et al. An analysis of respiratory induced kidney motion on four-dimensional computed tomography and its implications for stereotactic kidney radiotherapy. Radiat Oncol. 2013;8:248.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Heinzerling JH, Anderson JF, Papiez L, Boike T, Chien S, Zhang G, et al. Four-dimensional computed tomography scan analysis of tumor and organ motion at varying levels of abdominal compression during stereotactic treatment of lung and liver. Int J Radiat Oncol Biol Phys. 2008;70(5):1571–8.

    Article  PubMed  Google Scholar 

  74. Kim DWN, Medin PM, Timmerman RD. Emphasis on repair, not just avoidance of injury, facilitates prudent stereotactic ablative radiotherapy. Semin Radiat Oncol. 2017;27(4):378–92.

    Article  PubMed  Google Scholar 

  75. Singh AK, Winslow TB, Kermany MH, Goritz V, Heit L, Miller A, et al. A pilot study of stereotactic body radiation therapy combined with cytoreductive nephrectomy for metastatic renal cell carcinoma. Clin Cancer Res. 2017;23(17):5055–65.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Weichselbaum RR, Liang H, Deng L, Fu YX. Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol. 2017;14(6):365–79.

    Article  CAS  PubMed  Google Scholar 

  77. Hannan R, Margulis V, Chun SG, Cannon N, Kim D, Abdulrahman RE, et al. Stereotactic radiation therapy of renal cancer inferior vena cava tumor thrombus. Cancer Biol Ther. 2015;16(5):657–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358(9286):966–70.

    Article  CAS  PubMed  Google Scholar 

  79. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345(23):1655–9.

    Article  CAS  PubMed  Google Scholar 

  80. Correa RJ, Rodrigues GB, Chen H, Warner A, Ahmad B, Louie AV. Stereotactic ablative radiotherapy (SABR) for large renal tumors: a retrospective case series evaluating clinical outcomes, toxicity, and technical considerations. Am J Clin Oncol. 2018;41(6):568–75.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Texas Southwestern Medical Center, Radiation Oncology, Dallas, TX, USA

    Osama Mohamad

  2. University of Texas Southwestern Medical Center, Radiation Oncology and Neurological Surgery, Dallas, TX, USA

    Robert D. Timmerman

  3. University of Texas Southwestern Medical Center, Radiation Oncology and Immunology, Dallas, TX, USA

    Raquibul Hannan

Authors
  1. Osama Mohamad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert D. Timmerman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Raquibul Hannan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Raquibul Hannan .

Editor information

Editors and Affiliations

  1. Mayo Clinic, Radiation Oncology, Mayo Clinic School of Medicine Radiation Oncology, Jacksonville, FL, USA

    Daniel M. Trifiletti

  2. Department of Radiation Oncology, Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, OH, USA

    Samuel T. Chao

  3. Sunnybrook Odette Cancer Centre, Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada

    Arjun Sahgal

  4. University of Virginia, Departments of Neurological Surgery and Radiation Oncology, Charlottesville, VA, USA

    Jason P. Sheehan

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Mohamad, O., Timmerman, R.D., Hannan, R. (2019). Stereotactic Ablative Radiotherapy (SAbR) for Primary Renal Cell Carcinoma. In: Trifiletti, D., Chao, S., Sahgal, A., Sheehan, J. (eds) Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy. Springer, Cham. https://doi.org/10.1007/978-3-030-16924-4_26

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-16924-4_26

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-16923-7

  • Online ISBN: 978-3-030-16924-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation